（一）系统对接。国家医保局依托全国统一的医保信息平台建设医保影像云索引共享模块。试点地区医 保部门统筹指导地方影像云数据共享中心做好与当地医保影像云索引共享模块的对接、联调等工作，做 好技术支撑。 （二）数据上传。按照《影像检查数据上传服务接口文档》（附件1）要求，试点地区医保部门指导当 地医疗机构、检查检验机构将本机构放射检查类项目的原始影像数据、"医保影像云索引"及数据集及 时、准确、规范上传至地方影像云数据共享中心；指导地方影像云数据共享中心将"医保影像云索引"及 数据集上传至当地医保影像云索引共享模块。 （三）数据规范。试点地区医保部门要督导当地医疗机构、检查检验机构严格按照国家制定的《"医保 影像云索引"方案》（附件2）编制及上传"医保影像云索引"，并指导地方影像云数据共享中心对机构上 传的"医保影像云索引"进行检查核验。 国家医疗保障局办公室发布关于开展医保影像云索引上传试点工作的通知。根据《放射检查类医疗服务 价格项目立项指南（试行）》中的影像资料上传和价格减收要求，征集有条件的地区开展医保影像云索 引上传试点工作。试点地区医保部门指导当地医疗机构、检查检验机构应用统一的编制方案，编制规 范、准 ...

Investment Rating - The report does not explicitly state an investment rating for the industry [2] Core Insights - The pharmaceutical and biotechnology index rose by 6.02% during the period from February 5 to February 14, outperforming the Wind All A index (5.3%) and the CSI 300 index (3.19%) [2][7] - The AI + healthcare sector continues to strengthen, with sequencing and large models being the strongest directions [2][7] - The introduction of the medical insurance imaging cloud index by the National Medical Insurance Bureau aims to facilitate medical data sharing, reduce redundant examinations for patients, and enhance the efficiency of medical services [2][11] - Chinese innovative pharmaceutical companies are reshaping the global pharmaceutical innovation landscape by leveraging high-quality, low-cost talent and a progressive innovation approach [2][11] Summary by Sections Market Weekly Review - The pharmaceutical and biotechnology index increased by 6.02%, with hospitals (14.31%), medical devices (12.54%), and medical research outsourcing (10.57%) showing strong performance [7][8] - The top three performing stocks were BGI Genomics (75.25%), Dian Diagnostics (73.59%), and Meinian Health (49.08%) [9] Industry News and Key Company Announcements - The National Medical Insurance Bureau launched the medical imaging cloud index to improve data sharing among medical institutions [11] - Anke Bio plans to invest over 200 million yuan in Weisheng Pharmaceutical, focusing on long-acting growth hormone therapies [12] - The report highlights various collaborations and approvals in the industry, including partnerships for drug development and clinical trial advancements [14][16]